Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;56(3):709-712.
doi: 10.1038/s41409-020-01045-4. Epub 2020 Sep 3.

Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT

Robert Pytlík  1   2 , Blanka Vacková  3 , Eva Konířová  3 , Marie Trnková  3 , Petra Blahovcová  3 , David Pohlreich  3 , Kamila Polgárová  3 , Pavel Klener Jr  3   4 , Kateřina Benešová  3 , Kateřina Kopečková  5 , Jan Pirnos  6 , Marek Trněný  3
Affiliations

Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT

Robert Pytlík et al. Bone Marrow Transplant. 2021 Mar.
No abstract available

PubMed Disclaimer

References

    1. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–90. - PubMed - PMC - DOI
    1. Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32:3490–6. - PubMed - DOI
    1. Davison K, Chen BE, Kukreti V, Couban S, Benger A, Berinstein NL, et al. Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial. Ann Oncol. 2017;28:622–7. - PubMed - DOI
    1. van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35:544–51. - PubMed - DOI
    1. Jantunen E, Canals C, Rambaldi A, Ossenkoppele G, Allione B, Blaise D, et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica. 2008;93:1837–42. - PubMed - DOI

Publication types

MeSH terms

LinkOut - more resources